ADVL0821; A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody NSC #742460) in Children With Relapsed/Refractory Solid Tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors.
Description
The purpose of this study is to determine the response rate to IMC-A12 (cixutumumab) administered in various strata of recurrent/refractory malignant solid tumors in childhood and young adulthood, to further define and describe the toxicities of IMC-A12, and to further characterize the pharmacokinetics of IMC-A12.
Details
| Condition | Solid Tumor |
|---|---|
| Age | 1years - 30years |
| Clinical Study Identifier | TX4271 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.